nach oben

Erschienen in:

01.12.2012 | Special Situations in the Management of Hypertension (T Kotchen, Section Editor)

Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation

verfasst von: Guido Grassi, Gino Seravalle, Gianmaria Brambilla, Michele Bombelli, Raffaella Dell’Oro, Edoardo Gronda, Giuseppe Mancia

Erschienen in: Current Hypertension Reports | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Therapeutic interventions aimed at reducing high blood pressure still encompass a number of difficulties and limitations. This is the case particularly in resistant hypertension, i.e. a condition characterized by a very high cardiovascular risk. Carotid baroreceptor stimulation and renal sympathetic nerves ablation represent new approaches in the treatment of this condition. This paper will provide a comparison of the effects of the two procedures, highlighting their effects on blood pressure, metabolic profile, target organ damage, safety and tolerability profile.

Grassi G, Seravalle G, Trevano FQ, Dell'Oro R, Mancia G. Blood pressure control and antihypertensive treatment. Curr Vasc Pharmacol. 2012;10:506–11.CrossRefPubMed

Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29:610–8.CrossRefPubMed

•• Mancia G, De Backer G, Dominiczak A, Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87. The document includes the most recent recommendations on diagnosis and treatment of hypertension made by European experts.CrossRefPubMed

Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present and future. Curr Hypertens Rep. 2010;12:61–6.CrossRefPubMed

Katholi RE, Rocha-Singh KJ, Goswami NJ, Sobotka PA. Renal nerves in the maintenance of hypertension. a potential therapeutic target. Curr Hypertens Rev. 2010;12:196–204.CrossRef

Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19:2063–70.CrossRefPubMed

Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens. 2007;25:747–50.CrossRefPubMed

Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007;25:891–4.CrossRefPubMed

Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118:42–8.CrossRefPubMed

10.

•• Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19. The document by the American Heart Association and High Blood Pressure Council provides important recommendations and useful flowcharts on how to diagnose and manage resistant hypertension.CrossRefPubMed

11.

Václavík J, Sedlák R, Plachý M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069–75.CrossRefPubMed

12.

Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690–7.CrossRefPubMed

13.

Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens. 2010;23:1052–8.CrossRefPubMed

14.

•• Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619–26. This is the first report on the acute sympathoihibitory effects of carotid baroreflex activation in resistant hypertension.CrossRefPubMed

15.

Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932–4.CrossRefPubMed

16.

•• Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81. This is the first report on the blood pressure lowering effects of renal denervation in resistant hypertension.CrossRefPubMed

17.

•• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9. The paper reports the results of the first randomized investigation on renal denervation.CrossRefPubMed

18.

•• Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol. 2011;58:765–73. This is the first randomized study assessing the effects of carotid baroreceptor stimulation in resistant hypertension.CrossRefPubMed

19.

Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.CrossRef

20.

Krum H, Barman N, Schlaich M, et al. Long-term follow-up of catheter-based renal denervation for resistant hypertension confirms durable reduction of blood pressure values. J Am Coll Cardiol. 2012;59:E1704.CrossRef

21.

Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation—an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837–41.CrossRefPubMed

22.

• Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6. The results of this study provide evidence on the favorable metabolic effects of carotid baroreceptor activation.CrossRefPubMed

23.

Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559–65.CrossRefPubMed

24.

Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991–6.CrossRefPubMed

25.

Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9.CrossRefPubMed

26.

Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P, et al. Improved cardiac structure and function with chronic tretament using an implantable device in resistant hypertension: results from european and United States Trials of the Rheos System. J Am Coll Cardiol. 2011;57:1787–8.CrossRefPubMed

27.

Hering D, Mahfoud F, Walton As, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:pages to be determined.

28.

Scheffers IJM, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254–8.CrossRefPubMed

Titel: Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation
verfasst von: Guido Grassi
Gino Seravalle
Gianmaria Brambilla
Michele Bombelli
Raffaella Dell’Oro
Edoardo Gronda
Giuseppe Mancia
Publikationsdatum: 01.12.2012
Verlag: Current Science Inc.
Erschienen in: Current Hypertension Reports / Ausgabe 6/2012
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-012-0312-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?

Progression of Prehypertension to Hypertension in Adolescents

Ambulatory Blood Pressure Monitoring in Pediatric Renal Transplantation

Mechanisms and Consequences of Inflammatory Signaling in the Myocardium

Birth Weight and Childhood Blood Pressure

Mitochondria, Myocardial Remodeling, and Cardiovascular Disease